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Introduction: Acute effects of incidental cardiac irradiation in 
patients treated for thoracic cancer are not well characterized. We 
evaluated longitudinal changes in cardiac biomarkers for patients 
undergoing conformal radiation therapy (RT) with thoracic malig-
nancies with high-dose cardiac exposure.
Methods: Twenty-five patients enrolled in a prospective trial 
(February 2009‒December 2012) received more than or equal to 45 
Gy to the thorax, with pretreatment estimates of more than or equal to 
20 Gy to the heart. Chemotherapy was allowed except for doxorubi-
cin or fluorouracil. Electrocardiographic (ECG), troponin-I (TnI), and 
brain natriuretic peptide (BNP) measurements were obtained before 
RT, within 24 hours of the first fraction, at the end of RT, and at first 
follow-up (1–2 months). These biomarkers were quantified at specific 
times and changes from baseline were evaluated with paired t tests.
Results: The median heart dose was 25.9 Gy (range 10.1‒35.1 Gy). 
After the first RT fraction, no changes were noted in ECG or median 
TnI or BNP levels; at the end of RT, two patients had elevated TnI and 
BNP, but neither difference was statistically significant. At first follow-
up, TnI had returned to normal but the median BNP remained elevated 
(p = 0.042). BNP did not increase over time in the 18 patients who 
received only RT. Twelve patients experienced acute ECG changes dur-
ing RT, which resolved in seven patients by the next measurement. No 
patients experienced clinically significant RT-related events.
Conclusion: Increases in BNP and ECG changes were observed dur-
ing high doses of radiation to the heart. The findings of this pilot 
study warrant further investigation and validation.
Key Words: Cardiac toxicity, Radiation therapy, Lung cancer, Brain 
natriuretic peptide.
(J Thorac Oncol. 2014;9: 1554–1560)
Radiation therapy (RT) for cancer that involves the thorax sometimes involves unavoidable exposure of the heart to 
high radiation doses, even when advanced RT technologies are 
used. Although the long-term effects of low-dose cardiac expo-
sure are relatively well known, the acute effects, if any, are not. 
Moreover, most prior studies have focused on the long-term 
effects of radiation among survivors of Hodgkin’s lymphoma 
or patients receiving radiation for left-sided breast cancer, and 
most involved exposure of large portions of the heart to low 
radiation doses.1–5 The conclusions from these studies cannot 
be extrapolated to patients being treated for thoracic malig-
nancies such as lung cancer for several reasons. First, with the 
advent of increasingly conformal RT techniques, the dose dis-
tributions across the heart can differ substantially, with focal 
regions receiving high doses but other portions spared almost 
completely. Second, patients being treated for lung cancer 
often differ from those treated for breast cancer or Hodgkin’s 
lymphoma in that they tend to be older and to have underlying 
cardiopulmonary conditions such as coronary artery disease 
or chronic obstructive pulmonary disease. For these reasons, 
heart exposure for patients being treated for thoracic malig-
nancies, with modern techniques, should be studied separately 
from that for patients with other forms of cancer.
The purpose of this study was to prospectively evaluate 
biomarkers of cardiac function among patients receiving high-
dose conformal RT for thoracic malignancies. Specifically, 
we quantified brain natriuretic peptide (BNP) and troponin-
I (TnI) levels, and electrocardiographic (ECG) differences, 
before, during, and after RT, and we assessed whether cardiac 
dose was associated with changes in these values over time. 
We also documented clinical events to determine whether the 
occurrence of such events correlated with changes in these 
biomarkers.
PATIENTS AND METHODS
Patient Selection
This study was approved by the appropriate institu-
tional review board at The University of Texas MD Anderson 
Cancer Center. Patients were enrolled from February 2009 to 
December 2012. Inclusion criteria were having (1) a primary 
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thoracic malignancy (lung cancer, esophageal cancer, thy-
moma, or malignant mesothelioma) and (2) an estimated 
mean cardiac dose of more than or equal to 20 Gy at treatment 
simulation (assessed by the treating physician). Our institu-
tion treats approximately 200 patients per year definitively 
for lung cancer, and as such the study was initially designed 
to include patients who received only RT. However, initially 
there were difficulties with enrollment because many patients 
who had a mean heart dose more than 20 Gy received che-
motherapy or had other histologies (e.g., mesothelioma). At 
that point, in late 2011, the enrollment criteria were expanded 
to include patients with other histologies and patients treated 
with concurrent chemotherapy as long as the chemotherapy 
regimen did not include doxorubicin or fluorouracil owing to 
the potential cardiotoxicity of those drugs. Enrollment then 
increased substantially and the trial was closed in the next 
year. Exclusion criteria of the study were a recent (within 3 
months) history of cardiac events (myocardial infarction, 
decompensated heart failure, or myocarditis/pericarditis) or 
renal failure (serum creatinine ≥2.0), or having a pulmonary 
embolus during the month before RT. Patients with a remote 
history of these events were not excluded because we sought 
to evaluate acute changes regardless of cardiac history.
Study Evaluations
All patients underwent a complete history and physical 
examination and ECG, BNP, and troponin level measurements 
before study entry. ECG measurements were obtained with 
12-lead devices, and blood samples were drawn for BNP and 
TnI assessment after the first RT fraction, on the last day of 
radiation or chemoradiation, and at the first follow-up visit 
(1–2 months after completing RT). These measurement points 
were chosen to address the primary study aim, that is, deter-
mine whether high radiation doses led to acute changes in 
these cardiac biomarkers or ECG findings; a future aim was 
to determine whether such changes could be associated with 
subsequent long-term events.
Heart Contouring
For all patients, the heart was contoured by using a 
model-based segmentation method that was then adjusted 
manually to ensure that the entire structure was encompassed. 
For the purposes of treatment planning, the heart was defined 
superiorly as directly inferior to the aortic arch through the 
apex, and included both atria and ventricles. The pericardium 
was also encompassed within the heart contour.
Cardiac Biomarkers
For the cardiac biomarker analysis, we chose to assess 
TnI because it is a more sensitive measure of myocardial 
injury than is creatine kinase-myocardial band (CK-MB) or 
troponin T (TnT). We chose to assess BNP as an indicator of 
left ventricular function and congestive heart failure.
TnI levels were measured with the Unicel Dxl Access 
Immunoassay System (Beckman Coulter, Brea, CA), in 
which concentrations of the analyte are determined from a 
stored, multipoint calibration curve. The detection limit of 
this assay for TnI is 0.03 ng/ml (normal range 0–0.03 ng/ml, 
reportable range 0.03–100 ng/ml). BNP was measured by 
using the Triage Method with a Beckman Coulter UniCel Dxl 
600 Access Immunoassay system (normal range 0–100 pg/
ml; reportable range 1–5000 pg/ml). The sensitivity, specific-
ity, and negative predictive value of troponin for myocardial 
infarction has been shown in previous studies to be 85% or 
higher, whereas the positive predictive value ranges from 65% 
to almost 90%.6,7
Blinded Analysis of Electrocardiograms
All ECGs were analyzed after acquisition by a cardiolo-
gist (W.Y.) in a blinded manner for the following characteris-
tics: normal ECG, sinus tachycardia/bradycardia, conduction 
abnormalities (e.g., bundle branch block, atrial fibrillation), 
and ischemic changes. Subsequent ECGs were then analyzed 
to determine whether any acute changes had resolved.
Statistical Methods
Our primary objective was to investigate (1) the rela-
tionship between cardiac radiation dose and cardiac bio-
marker levels and (2) the temporal relationship between RT 
delivery and anticipated elevation of cardiac biomarkers. 
The distribution of BNP levels was reported as baseline (i.e., 
before RT) and change over time. Paired t tests were used to 
assess whether BNP levels changed over time, specifically if 
the change in mean levels was different than 0. Repeated mea-
sures regression analysis was then used to determine the effect 
of heart dose and time since baseline on BNP level. Ninety-
five percent confidence intervals (CIs) were determined for 
the mean change in BNP from baseline to day 1 of RT, to the 
end of RT, and to the first follow-up visit. Repeated measures 
regression analysis was used to assess the time since base-
line on BNP level and to identify any statistically significant 
increases in BNP level over time. We also included an inter-
action term for MHD and time in our model to allow for the 
possibility that the effect of MHD on change in BNP varied 
with time. Because of the repeated measures analysis, we had 
40 degrees of freedom for testing the interaction term and the 
term for time, because patients contribute data at each time 
point. Finally, we used the Spearman correlation to determine 
the correlation between mean heart radiation dose and change 
in BNP, both at the end of RT and at the 1- to 2-month fol-
low-up period. These analyses were then repeated for the 18 
patients who received only RT to identify trends without the 
potential confounding effect of chemotherapy.
A Bonferroni correction was used in the sample-size 
justification based on tests of the correlation between radia-
tion dose and the change from baseline at three different time 
points for all patients and for patients who received RT alone, 
for a total of six tests. With 25 patients, we had 80% power to 
detect a correlation of 0.60 or greater, with a one-sided signifi-
cance level of 0.008.
RESULTS
Patient Characteristics
Characteristics of the 25 patients enrolled in this study 
are listed in Table 1. Most patients (72%) were male and had 
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received RT in conventionally fractionated regimens, with 
prescribed doses ranging from 45 to 50 Gy (to target micro-
scopic disease after surgery) to 66 to 70 Gy as definitive RT. 
Most patients had preexisting cardiac conditions, primarily 
hypertension (52%) and hyperlipidemia (28%), with 48% of 
patients having more than one preexisting condition.
Changes in Troponin-I and 
Brain Natriuretic Peptide
All patients had undetectable TnI levels at baseline 
(before RT). Two of the 25 patients experienced increases in 
TnI levels during RT. One patient had a history of thymic car-
cinoma but no preexisting cardiac conditions and was treated 
with 66 Gy in 2-Gy fractions to the anterior mediastinum; 
the mean heart dose was 20.2 Gy and the V
40
 was 28%. This 
patient’s TnI level increased from undetectable (<0.03 ng/ml) 
before RT to 0.07 ng/ml at the end of RT, and had returned 
to an undetectable level at the first follow-up visit. The other 
patient had a history of hypertension and diabetes mellitus and 
received RT for malignant pleural mesothelioma to 60 Gy in 
2.4-Gy fractions to the gross tumor volume. This patient also 
experienced an increase in TnI from undetectable before RT to 
0.03 ng/ml at the end of RT, with TnI returning to undetectable 
levels at the first follow-up visit.
Because changes in BNP were found to not be corre-
lated with mean heart dose on day 1 (Spearman correlation 
r = 0.15, p = 0.51), at the end of RT (r = 0.23, p = 0.27), or at 
the first follow-up visit (r = 0.18, p = 0.46), we then examined 
BNP changes over time in an exploratory analysis. All patients 
had BNP measurements at the end of RT, and 19 of the 25 
patients had BNP measurements at the first follow-up period. 
Changes in BNP over the course of treatment for the entire 
group are shown in Figure 1A and Table 2, with a tabulation 
of the correlation coefficients in Table 2. One patient had a 
greatly increased BNP level after one fraction (684 pg/ml) that 
then decreased and remained at approximately normal levels 
thereafter; that patient had received concurrent chemotherapy 
with cisplatin and etoposide.
Among the entire group, the mean change in BNP from 
baseline to the end of RT was statistically significant (95% 
CI 3.39 to 46.53, p = 0.025), and the mean change in BNP 
from baseline to first follow-up was also statistically signifi-
cant (95% CI 6.96 to 79.77, p = 0.022). No difference was 
found in mean change in BNP from baseline to after one frac-
tion of RT (95% CI −25.43 to 101.69, p = 0.227). Repeated 
measures regression analysis revealed no effect of mean heart 
dose (p = 0.167) or time since baseline on change from base-
line for BNP levels (p = 0.104).
These analyses were then repeated for the 18 patients 
who did not receive concurrent chemotherapy. Again, neither 
mean heart dose (p = 0.19) nor time since baseline (p = 0.92) 
affected change from baseline in BNP level. Moreover, no 
interaction effect was found between mean heart dose and 
time because of baseline. Changes in BNP levels over time 
for patients who received only RT are also shown in Table 3. 
Figure 1B, C and Table 4 compare changes in BNP at dif-
ferent time points in those patients receiving chemoradia-
tion (Figure 1B) and those receiving RT alone (Figure 1C). 
It is evident that the magnitude of changes was increased 
in those patients receiving chemotherapy, although the dif-
ferences were not statistically significant (p > 0.008 for all 
timepoints).
Electrocardiogram Changes Associated 
with Radiation Therapy
Twelve patients were found to have changes in ECG 
readings after initiating RT (Table 5), with the two most com-
mon being T-wave changes and poor R-wave progression. 
The effects occurred at various times in relation to RT, and 
in seven of these 12 patients (58%), the ECG changes had 
resolved on subsequent studies and were asymptomatic. In no 
patient was intervention deemed to be required as a result of 
these ECG abnormalities.
Clinical Events Related to Radiation Therapy
No patient experienced a cardiac event related to RT at 
any time during the study.
TABLE 1.  Patient Characteristics (n = 25)
Characteristic
Value or  
No. of Patients  
(% or Range)
Age at diagnosis, yr
  Median (range) 63 (31–75)
Sex
  Male 18 (72)
  Female 7 (28)
Tumor type
  Mesothelioma 16 (64)
  NSCLC 5 (20)
  Thymoma 2 (8)
  Othera 2 (8)
Prescription radiation dose, Gy
  Median (range) 50 (45–70)
Radiation fraction size, Gy
  Median (range) 2 (1.8–3)
Cardiac comorbid conditions
  Hypertension 13 (52)
  Hyperlipidemia 7 (28)
  Diabetes mellitus 6 (24)
  Arrhythmia 2 (8)
  Myocardial infarction 1 (4)
Mean heart dose, Gy
  Median (range) 26.5 (10.1–35.1)
Heart volume receiving at least 40 Gy (V
40
), %
  Median (range) 23.4 (0.63–43.26)
Mean lung dose, Gy
  Median (range) 18.1 (6.6–21.7)
Concurrent chemotherapy
  Yes 7 (26)
  No 18 (72)
aOther histologies were small cell lung cancer, atypical carcinoid.
NSCLC, non–small-cell lung cancer.
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DISCUSSION
In this prospective study of blood-based cardiac func-
tion biomarkers and ECG changes among patients receiving 
high radiation doses to the heart from conformal techniques, 
our pertinent findings are as follows. First, most patients did 
not experience any discernible changes in TnI, either after 
exposure to a single fraction of RT or at long-term follow-up 
(at the end of RT, 1–2 months after the completion of RT). 
Second, we found a trend toward increased BNP at the end 
of RT and at the 1- to 2-month follow-up period relative to 
baseline levels. However, the quantitative changes from base-
line were modest and were not associated with any clinically 
meaningful events. Furthermore, we did not find an association 
between heart dose and cardiac biomarkers, though acknowl-
edging that all the patients received relatively high heart doses 
in this analysis. Third, the correlation of BNP levels with time 
was substantially attenuated for patients receiving only RT, 
suggesting that concurrent chemotherapy increases any acute 
RT effects on the heart. Finally, slightly less than half of all 
patients had ECG changes at various times after RT, but most 
FIGURE 1.  Change in the level of brain natriuretic peptide (BNP) with time in (A) all patients (n = 25), (B) patients receiving 
concurrent chemoradiation (n = 7), and (C) patients receiving only radiation therapy (n = 18). The box represents the inter-
quartile range (IQR), and the shaded region is a 95% CI for the median. The whiskers are drawn to the nearest value and not 
beyond 1.5 × IQR from the top (quartile 3) or bottom (quartile 1) of the box. Outliers are those values beyond the whiskers.
TABLE 2.  Correlation Coefficients and p Values of Changes of BNP with Time after High-Dose Cardiac Radiation
All Patients Patients with Radiation Only Patients with Chemotherapy
Correlation p Value1 Correlation p valuea Correlation p valuea
Day 1 0.15 0.51 0.42 0.11 −0.32 0.48
End of RT 0.23 0.27 0.40 0.10 −0.32 0.48
Month 1–2 0.18 0.46 0.20 0.51 −0.14 0.79
ap Values should be compared with a significance level of 0.0056 to account for multiple testing (p = 0.05/9 = 0.0056).
RT, radiation therapy.
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of these abnormalities were nonspecific, most had resolved 
upon subsequent evaluation, and none required intervention.
Although some studies have assessed short-term changes 
in cardiac biomarker levels after RT,8,9 few have analyzed 
such changes after high-dose RT delivered via modern, highly 
conformal techniques. To our knowledge, the trial most similar 
to ours was conducted by investigators at Massachusetts General 
Hospital, who assessed the effect of RT on TnT, CK-MB, and 
aminoterminal pro-brain natriuretic peptide (NT-proBNP) 
levels in 30 patients who received either three-dimensional 
TABLE 3.  Brain Natriuretic Peptide Levels (in pg/ml) at Each Study Visit
Measurement Time No. of Patients Mean Standard Deviation Minimum Median Maximum
All patients
  Baseline 25 94.68 133.55 4.00 54.00 681.00
  Day 1 23 132.26 165.05 15.00 70.00 684.00
  End of RT 25 119.64 165.21 16.00 95.00 858.00
  Month 1–2 19 139.84 176.33 10.00 68.00 726.00
Patients receiving only RT
  Baseline 18 120.22 150.21 12.00 100.50 681.00
  Day 1 16 113.81 125.33 18.00 83.00 512.00
  End of RT 18 140.72 190.92 16.00 115.00 858.00
  Month 1–2 13 170.00 203.49 28.00 89.00 726.00
RT, radiation therapy.
TABLE 4.  Comparison of Changes in Brain Natriuretic Peptide (BNP) Among Those Patients that Received Radiation Therapy 
Alone vs. Those with Chemoradiation
Mean Change in BNP
p Value of Means  
(Chemotherapy vs. RT Alone)a Median Change in BNP
p Value of Medians  
(Chemotherapy vs. RT Alone)a
Day 1 RT alone: −8.81
ChemoRT: 145.43
p = 0.12 RT alone: 2.5
ChemoRT: 42.0
p = 0.038
End of RT RT alone: 20.50
ChemoRT: 36.43
p = 0.51 RT alone: 2.5
ChemoRT: 41.0
p = 0.12
Month 1–2 RT alone: 40.46
ChemoRT: 49.67
p = 0.81 RT alone: 15.0
ChemoRT: 30.0
p = 0.47
It is clear that the changes are always greater in the patients receiving chemotherapy, though not statistically significant, possibly secondary to small numbers of patients. The 
differences between the two groups are also more substantial during the earlier time periods.
ap Values should be compared with 0.008 due to multiple testing (0.05/6 = 0.008).
RT, radiation therapy.
TABLE 5.  Summary of Electrocardiographic Changes During and After Radiation Therapy
Patient
Mean Heart 
Dose, Gy
Concurrent 
Chemotherapy Measurement Time Description of Change
Change Resolved 
on Next ECG
1 20.3 Yes Follow-up Septal T-wave changes Unknowna
2 25.3 No After first fraction Septal T-wave changes No
3 34.1 No Follow-up Extensive T-wave changes No
4 35.1 No Follow-up Anterior/lateral T-wave changes No
5 28.4 No End of RT Septal and lateral T-wave changes No
6 27.1 Yes End of RT Prolonged QT interval Yes
7 30.1 No End of RT Prolonged QT interval Yes
8 10.1 No End of RT Septal ST changes Yes
9 29.7 Yes Follow-up Poor R-wave progression Yes
10 28.2 No After first fraction Poor R-wave progression Yes
11 18.0 No After first fraction Poor R-wave progression Yes
12 20.0 No After first Fraction/end of RT Septal T-wave changes/ST Junction depression Yes/No
aThis patient did not undergo subsequent ECG testing.
ECG, electrocardiogram; RT, radiation therapy.
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conformal therapy or intensity-modulated radiation therapy, 
most (24 patients) with concurrent chemotherapy; 18 of these 
patients had lung cancer. Those investigators found that TnT 
remained undetectable in 29 patients, and none of the other 
biomarkers changed significantly after RT, with or without 
chemotherapy.10 However, that study differed from ours in that 
the cardiac RT doses were approximately half of those in the 
current study. Moreover, the minimum mean heart dose in the 
Mass General study was 0.6 Gy, and almost no patients received 
doses above 50 Gy (median V
50
 = 0%). At doses such as these, 
one could surmise that no changes in cardiac biomarkers were 
observed because the heart dose was insufficient to cause any 
differences, at least during the acute period.
Even with the substantially higher heart dose in the cur-
rent study, our findings showed that troponin levels did not 
change in most patients. However, two patients in this study 
did have temporarily detectable TnI levels at the end of treat-
ment. Cardiac troponin is a biomarker of cardiac injury that is 
undetectable in healthy subjects.11 However, even very small 
elevations in troponin levels can have important prognos-
tic significance. For example, at least one study showed that 
patients with troponin levels exceeding more than 0.01 ng/ml 
had worse cardiac outcomes and significantly increased mor-
tality compared with patients with troponin levels less than 
0.01 ng/ml.12 Notably, the patients with small elevations in 
troponin in our study had no other risk factors that would pre-
cipitate a troponin leak. Therefore, these changes could rep-
resent a transient membrane leak from cardiac myocytes due 
to direct radiation damage. Alternatively, the leakage could be 
related to other factors, as has been observed in endurance 
athletes with elevated troponin levels but no evidence of myo-
cardial necrosis on magnetic resonance imaging (MRI).13
We also found that high heart doses led to increases in 
BNP levels at the end of RT and at the first follow-up visit, 
again suggesting that the higher radiation dose used here led 
to more marked changes than previously reported for low-dose 
RT. The changes in BNP seem to have been more pronounced 
for patients who received chemotherapy. Interestingly, base-
line BNP levels were also slightly elevated in this study, 
for reasons that are not apparent when examining the data. 
However, factors such as tachycardia can also increase BNP 
and were not assessed in this analysis. An increase in BNP 
level may represent direct myocyte inflammation and poten-
tial residual diastolic dysfunction related to RT. One patient 
receiving concurrent chemoradiation had a sharp increase 
in BNP after one RT fraction that quickly declined thereaf-
ter. The reason for this observation is unclear but could be 
related to temporary cardiac overload with the administration 
of chemotherapy. Prior analyses have shown that both small 
elevations in troponin and any elevation in BNP levels predict 
worse outcomes among patients with stable congestive heart 
failure.12 Although no large-scale trials have been published 
with long-term follow-up of biomarkers in patients receiving 
RT, increased BNP levels in patients with cancer have been 
linked with poor survival even in the absence of ventricular 
dysfunction or volume overload.14 Indeed, longer follow-up of 
the patients in the current study who experienced changes in 
biomarkers will determine the clinical relevance of short-term 
increases in such cases.
We also found that RT led to ECG changes in almost 
half of the patients in our trial. Although several studies have 
assessed the effect of systemic therapy regimens such as flu-
orouracil on cardiac rhythms,15 and the effect of RT on car-
diac devices,16,17 studies of high-dose RT and acute changes 
in ECG findings have been sparse and primarily limited to 
case reports.18 The most common alterations in ECG in the 
current study were septal T-wave changes and poor R-wave 
progression. Septal T-wave changes are nonspecific and can 
represent several acute and chronic processes, including elec-
trolyte abnormalities, anemia, and pH changes, as well as 
acute cardiac processes such as myocarditis, pericarditis, car-
diomyopathy, pulmonary emboli, and lung disease. The differ-
ential diagnosis of poor R-wave progression is also relatively 
broad and includes body habitus, ventricular hypertrophy, 
and myocardial infarction.19 In addition, both these changes 
can represent “normal variants,” although given the timing 
of these observations during and after RT, and the fact that 
most patients did not receive chemotherapy, it is reasonable 
to hypothesize that radiation to the heart caused these acute 
changes. We acknowledge that the overall clinical significance 
of acute changes in ECG patterns for patients receiving RT 
will need to be determined with long-term follow-up for the 
occurrence of subsequent clinical events.
This study did have limitations that constrain interpre-
tation of the results. The primary limitations were the small 
number of patients and the inability to detect causality using 
this study design, which were functions of the pilot nature of 
this prospective analysis. Indeed, our goal was not to provide 
definitive conclusions regarding the effect of high-dose RT 
on cardiac biomarkers in thoracic malignancies, but rather to 
observe if short-term trends could be observed in the acute 
setting. A second restriction is the limited ability to detect 
increases in TnI and BNP levels, which was a function of the 
sensitivity of the assays used. However, one could argue that 
the utility of detecting smaller changes in these markers is low, 
given the lack of clear clinical significance of smaller eleva-
tions. Another limitation was that cardiac events may be dif-
ficult to assess in patients with lung cancer and mesothelioma 
because such patients may also have other cardiopulmonary 
comorbidities. However, because the incidence of cardiac 
events was so low, any influence of this confounding factor 
was likely minimal in this study. Fourth was our inclusion of 
a patient who turned out to have a substantially smaller heart 
dose (10 Gy) than our intended minimum predicted during 
treatment planning (20 Gy). We ultimately chose to include 
this patient in the analysis because 10 Gy can be considered a 
moderate heart dose and because we wanted to maximize the 
amount of prospective data for analysis. We do not believe that 
including this patient had any major influence on our results 
or conclusions. We further included patients with a variety of 
tumor types, most notably mesothelioma. We are unaware of 
any findings suggesting that tumor histology would affect car-
diac toxicity, and thus the rationale for including these patients 
was the presumption that acute cardiac changes in troponin and 
ECG would depend primarily on RT dose in patients receiving 
high doses. Notably, however, no patients with mesothelioma 
were given concurrent chemotherapy with the RT, the use of 
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which seemed to have enhanced the cardiac changes observed 
in this study.
Finally, this study was designed with a short-term fol-
low-up period and a limited range of doses, thus restricting 
the capacity to detect a dose response, because our focus was 
on acute changes that may be associated with high cardiac 
dose. A more complete clinical analysis would entail follow-
up for at least 2 or 3 years and with an increased dose range; 
such a design presumably would reveal the impact of dose on 
both acute and late RT-related toxicity and thereby strengthen 
the associations observed in this analysis of acute effects. We 
are continuing to follow these patients and intend to pool the 
results of this study with those involving other patients with 
locally advanced disease to determine whether further toxicity 
arises that warrants longer follow-up with these metrics.
In conclusion, this prospective analysis of acute changes 
in cardiac biomarkers and ECG findings in patients receiving 
high cardiac radiation doses revealed differences in BNP lev-
els at the end of RT and at the first follow-up period. Nearly 
half of the patients studied also experienced ECG changes 
after RT, although these alterations may not be directly related 
to the RT. Finally, no patients experienced a clinically signifi-
cant cardiac event, implying either that the vast majority of 
such events are subclinical or that additional events could be 
identified in patients experiencing detectable variations in bio-
markers with long-term follow-up. This distinction should be 
answered in future studies that focus on cancer survivors who 
receive analogous dose distributions. Combining these studies 
with novel imaging techniques is also expected to help answer 
this question.
ACKNOWLEDGMENT
We sincerely thank Christine Wogan, MS, ELS, of MD 
Anderson’s Division of Radiation Oncology, for her work in 
reviewing and editing this manuscript.
REFERENCES
 1. Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mor-
tality in patients treated for Hodgkin’s disease. Cancer 1992;69:1241–1247.
 2. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differ-
ences in the extent of surgery for early breast cancer on local recurrence 
and 15-year survival: an overview of the randomised trials. Lancet. 
2005;366:2087–2106.
 3. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortal-
ity from heart disease after treatment of Hodgkin’s disease. JAMA 
1993;270:1949–1955.
 4. Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regur-
gitation after mediastinal radiation for Hodgkin’s disease: an echocardio-
graphic study. Heart 1996;75:591–595.
 5. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart dis-
ease in women after radiotherapy for breast cancer. N Engl J Med 
2013;368:987–998.
 6. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in 
early diagnosis of acute myocardial infarction. N Engl J Med 
2009;361:868–877.
 7. Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative 
changes in cardiac troponin concentrations in the early diagnosis of acute 
myocardial infarction. Circulation 2011;124:136–145.
 8. D’Errico MP, Grimaldi L, Petruzzelli MF, et al. N-terminal pro-B-type 
natriuretic peptide plasma levels as a potential biomarker for cardiac 
damage after radiotherapy in patients with left-sided breast cancer. Int J 
Radiat Oncol Biol Phys 2012;82:e239–e246.
 9. Hughes-Davies L, Sacks D, Rescigno J, Howard S, Harris J. Serum car-
diac troponin T levels during treatment of early-stage breast cancer. J Clin 
Oncol 1995;13:2582–2584.
 10. Kozak KR, Hong TS, Sluss PM, et al. Cardiac blood biomarkers in patients 
receiving thoracic (chemo)radiation. Lung Cancer 2008;62:351–355.
 11. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and deter-
minants of troponin T elevation in the general population. Circulation 
2006;113:1958–1965.
 12. Latini R, Masson S, Anand IS, et al.; Val-HeFT Investigators. Prognostic 
value of very low plasma concentrations of troponin T in patients with 
stable chronic heart failure. Circulation 2007;116:1242–1249.
 13. Scharhag J, Urhausen A, Schneider G, et al. Reproducibility and clini-
cal significance of exercise-induced increases in cardiac troponins and 
N-terminal pro brain natriuretic peptide in endurance athletes. Eur J 
Cardiovasc Prev Rehabil 2006;13:388–397.
 14. Burjonroppa SC, Tong AT, Xiao LC, Johnson MM, Yusuf SW, Lenihan 
DJ. Cancer patients with markedly elevated B-type natriuretic peptide 
may not have volume overload. Am J Clin Oncol 2007;30:287–293.
 15. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxic-
ity: revisited. Expert Opin Drug Saf 2009;8:191–202.
 16. Gomez DR, Poenisch F, Pinnix CC, et al. Malfunctions of implantable 
cardiac devices in patients receiving proton beam therapy: incidence and 
predictors. Int J Radiat Oncol Biol Phys 2013;87:570–575.
 17. Oshiro Y, Sugahara S, Noma M, et al. Proton beam therapy interfer-
ence with implanted cardiac pacemakers. Int J Radiat Oncol Biol Phys 
2008;72:723–727.
 18. Vasic N, Stevic R, Pesut D, Jovanovic D. Acute left bundle branch 
block as a complication of brachytherapy for lung cancer. Respir Med 
2011;105(Suppl 1):S78–S80.
 19. MacKenzie R. Poor R-wave progression. J Insur Med 2005;37:58–62.
